Nexalin study shows promise for Alzheimer's treatment with new brain stimulation technology
Summary: Nexalin Technology, Inc. announced positive results from a clinical trial of its Deep Intracranial Frequency Stimulation (DIFS) technology for patients with mild Alzheimer’s disease. The study showed significant improvements in memory and cognitive function compared to a control group.
The trial involved 46 patients, with those receiving DIFS showing notable gains in cognitive assessments. Functional MRI scans indicated increased neural activity and blood flow in the hippocampus, a key area for memory processing.
The treatment was well-tolerated, with only minor side effects reported. Nexalin plans to further explore DIFS technology in upcoming clinical trials to enhance its effectiveness.
This is article metrics. Combined, they form a significance score, that indicates how important the news is on a scale from 0 to 10.
My algorithm scores 10,000 news articles daily, and creates a single significance-ordered list of news.
Read more about how I calculate significance, or see today's top ranked news on the main page:
See today's news rankings